Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 clinical trial of MAX-001

Next Previous
Trial Profile

A Phase 2 clinical trial of MAX-001

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nefopam (Primary)
  • Indications Acute pain; Postoperative pain
  • Focus Therapeutic Use

Most Recent Events

  • 15 Jul 2026 According to Maxona Pharmaceuticals media release, company expects to enroll the first patients within the next few months and complete the dosing phase of this study very quickly.
  • 15 Jul 2026 According to Maxona Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) cleared New Drug (IND) Application for a Phase 2 clinical trial to evaluate MAX-001 for the treatment of acute pain.
  • 07 Aug 2025 According to Maxona Pharmaceuticals media release, company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for MAX-001, for the treatment of acute pain, in early Q3 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top